TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
ADCE-T02 enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors April 28, 2026
Promising Clinical Activity and Favorable Safety Profile Reported for ACE-106 in solid tumors April 21, 2026
C4 Therapeutics and Roche Enter New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) April 15, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with BMS to Discover and Develop Next-Gen T-cell Engagers for Solid Tumours April 15, 2026
Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
Oricell Therapeutics Closes $110 Million Pre-IPO Financing for Global Development of Solid Tumor CAR-T Therapies April 15, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First-Patient-In for Ph 1 Trial of IDE574 in Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer April 7, 2026
First-Patient-In for Ph 1 Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma April 7, 2026
FDA granted Fast Track designation for A2B543 for the treatment of germline heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express MSLN and have lost HLA-A*02 expression April 7, 2026
First Patient dosed in Ph 1 Trial of CLIO-8221 in Advanced HER2-Expressing Solid Tumors March 31, 2026
Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs March 24, 2026
Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818 for HR+/HER2- breast cancer and other solid tumor indications March 24, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC March 24, 2026
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies March 24, 2026
